• Merck Animal Health agreed to acquire poultry biodevice developer TARGAN for an undisclosed price, expanding Merck’s technology offering for commercial hatcheries.
• The deal is expected to close in Q3 2026, subject to customary closing conditions.
• TARGAN’s WingScan system automates chick gender sorting using vision technology, targeting throughput of up to 160,000 chicks per hour.
• The acquisition also adds high-speed ocular spray technology for administering vaccines to day-old chicks.
• Merck has been an investor in TARGAN since 2017 and one of its largest shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260610672968) on June 11, 2026, and is solely responsible for the information contained therein.